CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. The company’s work spans clinical development, regulatory filings, and the advancement of antibody-based therapies from early-stage research toward human studies.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of the anti-CD38 antibody CID-103 for immunology and transplant indications.
Trial planning, submissions, and execution activities supporting development programs.
Work on stable, high-concentration protein solutions for subcutaneous delivery.
Asiakkaat
CASI’s direct commercial customers are limited because the company is primarily a development-stage biopharmaceutical business. Its economic value is tied mainly to patients, clinicians, hospitals, and transplant centers that may eventually use CID-103, as well as regulators and research partners involved in clinical development.
Patients with chronic active renal allograft antibody-mediated rejection who may benefit from CID-103 if developed successfully.
Patients with immune thrombocytopenia and related autoimmune disorders targeted by the anti-CD38 program.
Clinical sites that enroll and treat patients in studies and would later administer the therapy in practice.
Authorities that review CTA and IND filings and determine whether clinical trials can proceed.
Potential collaborators or licensees that may support development, manufacturing, or commercialization.
Strategia
CASI’s strategy centers on advancing CID-103 through early clinical development and building evidence for its transplant and autoimmune indications. A second priority is improving drug formulation for subcutaneous administration, which could support usability and differentiation if development succeeds.
Clinical data is the main value driver for a development-stage biotech company.
Multiple indications can improve the asset’s commercial potential and reduce single-program risk.
A stable subcutaneous product could improve patient convenience and product differentiation.
Maantiede
CASI is operationally tied to the United States and China through its clinical and regulatory activities. The company’s principal executive office is in Beijing, while its product development program includes a U.S. IND and a Chinese CTA for CID-103.
Riskit
CASI faces classic clinical-stage biotech risks, including trial failure, safety concerns, and regulatory delays, because its value depends heavily on a single lead asset. The company also has execution risk tied to cross-border development and market access, plus financial and listing-related risks that can limit trading liquidity and investor confidence.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company’s value is concentrated in CID-103, so disappointing efficacy or safety data could materially impair prospects.
Kohdistuu: CID-103 trials
- Program concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A single lead asset creates limited diversification if the program underperforms or is terminated.
Kohdistuu: CID-103
- Regulatory delay or non-approvalVaikutus: KorkeaTodennäköisyys: Kohtalainen
CTA/IND approvals and later submissions are required to continue development and eventually commercialize the asset.
Kohdistuu: FDA and Chinese regulators
- Capital markets and listing riskVaikutus: KeskitasoTodennäköisyys: Korkea
Biotech development requires ongoing funding and market access, and trading venue changes can affect liquidity.
Kohdistuu: Equity financing and share trading
Kirjanpito
Harkinnanvaraiset erätClinical trial and development spending is expensed as incurred, so trial timing affects quarterly comparability.
Vaikutus: Operating loss and cash burn
Cross-border operations create currency gains and losses that can move reported earnings.
Vaikutus: Other income/expense
Any collaboration, license, or supply arrangement would require judgment on performance obligations and timing.
Vaikutus: Reported revenue and deferred revenue
Pipeline assets and related intangibles may require write-downs if development outcomes weaken.
Vaikutus: Balance sheet and earnings
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Zai Lab Ltd
ZLAB · Pharmaceutical Preparations
Zai Lab Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for oncology, immunology, neuroscience, and infectious diseases.
Silence Therapeutics plc
SLNCF · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
SAB Biotherapeutics, Inc.
SABSW · Biological Products, (No Diagnostic Substances)
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Päivitetty: 28.9.2026